The continuing objectives of this amended grant are to promote and augment the development of a basic cancer research center devoted to collaborative, innovative investigation at a fundamental level with an eye to future clinical cancer research endeavors. Scientists from different backgrounds and different academic departments are coordinating their on-going research efforts to mount a frontal attack on the various aspects of cancer research. Efforts will be concentrated in five research programs, each under the direction of a senior scientist, as follows: Program 1: Cellular Functions and Growth Control: Intracellular Mechanisms; Program 2; Cell structure, Growth and Regulation; Program 3: Control of Hematopoietic Cell Differentiation and Proliferation; Program 4: Growth and Differentiation of Mammalian Endocrine Cells; Program 5: Antigen Recognition and Cellular Activation in Immune Responses. Most of the scientists in each of these five programs have had longstanding collaborative research programs. It is our intention to expand these efforts of existing staff investigators and to recruit new investigators who can bring fresh ideas and new techniques into these collaborative research efforts. The Cancer Research Center will provide the environment for interplay among staff investigators of all five programs, who will be using advanced central research facilities. The NCI Cancer Centers staff has justifiably ruled that we are a Basic Cancer Research Center, but with their encouragement, we shall continue independent development of clinical cancer research initiatives promoted entirely by local funds. Accomplishments during the first three years of CCSG support include: increase in Staff Investigators from 60 to 80; recruitment of seven New Investigators; doubling use by Staff Investigators of Shared Core Research Facilities; renewal of one and acquisition of another program-project grant; acquisition and renovation of new Cancer Center laboratories; development of a new Program in Cancer Immunology; and major expansion of Cancer Center seminars and symposia for greater interaction among Staff Investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-06
Application #
2091519
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1987-07-01
Project End
1995-07-31
Budget Start
1993-08-20
Budget End
1995-07-31
Support Year
6
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Virginia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815

Showing the most recent 10 out of 539 publications